Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

IgG4 Related Disease Clinical Trial

Official title:
A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases

Status Not yet recruiting

Clinical Trial Summary

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Clinical Trial Description

This study includes three stages: screening period, treatment period and safety follow-up period. ;

Study Design

Related Conditions & MeSH terms

IgG4 Related Disease

Clinical Trial Details

NCT number	NCT05728684
Study type	Interventional
Source	Beijing Friendship Hospital
Contact
Status	Not yet recruiting
Phase	N/A
Start date	February 28, 2023
Completion date	February 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05662241` - A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease	Phase 3
Active, not recruiting	`NCT04540497` - A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease	Phase 3
Terminated	`NCT04918147` - Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)	Phase 2
Completed	`NCT04817553` - Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Recruiting	`NCT04602598` - Zanubrutinib in Patients With IgG4-Related Disease	Phase 2
Recruiting	`NCT06361745` - Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases	N/A